Posted by Michael Wonder on 15 Sep 2016
TGA approves Simponi for axial spondyloarthritis
15 September 2016 - The TGA has approved a new use for Simponi.
The TGA approved Simponi (golimumab) on 9 September 2016 for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence, who have had an inadequate response to, or are intolerant to, non-steroidal anti-inflammatory drugs.
